drugset
drugset / Trial / NCT04263519

A Pilot Open Labeled Study of Tacrolimus in Alzheimer's Disease.

NCT04263519 ↗

Phase 2 Withdrawn Massachusetts General Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

A Pilot open labeled study of Tacrolimus in Alzheimer's Disease.

Timeline

Start
2021-12-01
Primary completion
2022-12-01
Completion
2023-01-01

Outcome

Outcome not reported

Stopped: “Covid restrictions”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tacrolimus Small molecule — Oral

Indications

Alzheimer disease cognitive impairment with or without cerebellar ataxia